Study, year
Surveillance intensity
Number of patients randomized
Median observation time (months)
Overall recurrence rate (%)
Number of second bowel cancers
Radical reoperation rate (%)
5-year survival rate (%)
Ohlsson (1995)
Less
54
82
33
NR
17
67
More
53
32
29
75
Makela (1995)
Less
54
>60
39
NR
14
54
More
52
42
23
59
Schoemaker (1998)
Less
158
>60
NR
5
NR
70
More
167
3
76
Kjeldsen (1997)
Less
307
>60
26
3
NR
68
More
290
26
7
70
Pietra (1998)
Less
103
>60
19
1
10
58
More
104
25a
0
65
73b
Secco (2002)
Less
145
>60
53
NR
16
48
More
192
57
31
63
In 2013, Johnson et al.[12] summarized the then-current recommendations of the following institutions:
The National Comprehensive Cancer Network (Table 18.2).
Years posttreatmenta
1
2
3
4
5
>5
Office visit
2–4
2–4
2
2
2
0
Serum CEA levelb
2–4
2–4
2
2
2
0
Chest/abdominal/pelvic CTc
1
1
1
0–1
0–1
0
Colonoscopyd, e
1
0–1
0–1
0
0–1
0–1
Proctoscopyf, g
2
2
2
2
2
0
PET-CT scan is not routinely recommended.
The American Society of Clinical Oncology (Table 18.3).
Years posttreatmenta
1
2
3
4
5
>5
Office visit
2–4
2–4
2
2
2
0b
Serum CEA levelc, d
4
4
4
0
0
0
Chest/abdomen CTe
1
1
1
0
0
0
Colonoscopyf, g
1
0
1
0
1
0-1
Flexible proctosigmoidoscopyh
2
2
2
2
2
0
Routine blood tests (i.e., CBC, LFTs), fecal occult blood testing, yearly chest x-rays are not recommended.
Use of molecular or cellular markers should not influence the surveillance strategy.
The European Society for Medical Oncology (Table 18.4).
Years posttreatmenta
1
2
3
4
5
>5
Office visit
2
2
0
0
1
0–1
Rectosigmoidoscopy
2
2
0
0
0
0
Colonoscopyb
1
0
0
0
1
0–1
Imaging of liver, lungs
1
0
1
0
0
0
The value of regular clinical, laboratory and radiological examinations are not known.
The National Institute for Clinical Excellence (NICE) of the United Kingdom (Table 18.5).
Years posttreatmenta
1
2
3
4
5
>5
Office visitb, c
≥2
≥2
≥2
0
1
0
Serum CEA level
≥2
≥2
≥2
0Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
Get Clinical Tree app for offline access